Anticoagulant makers admit promo error

The makers of the new anticoagulant rivaroxaban  have told clinicians that material spruiking its 2012 patient familiarisation scheme contained an error on its effectiveness compared with warfarin.

Last month Bayer - the maker of rivaroxaban (Xarelto) - wrote to doctors across the country alerting them to inaccuracies in marketing material for its Patient Familiarisation Program, which offered the drug free of charge to AF patients.

The correction was triggered by “concerns raised by another company”, Bayer told Cardiology Update's sister

Latest

Trending